Serena Spudich

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremia
    Serena S Spudich
    Department of Neurology, University of California San Francisco, San Francisco, California, USA
    J Infect Dis 191:890-8. 2005
  2. pmc The cerebrospinal fluid proteome in HIV infection: change associated with disease severity
    Thomas E Angel
    Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA
    Clin Proteomics 9:3. 2012
  3. pmc Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection
    Lars Hagberg
    Department of Infectious Diseases, Sahlgrenska University Hospital, University of Gothenburg SE 41685 Sweden
    AIDS Res Ther 7:15. 2010
  4. pmc Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment
    Serena S Spudich
    Department of Neurology, University of California, San Francisco, USA
    BMC Infect Dis 5:98. 2005
  5. ncbi request reprint Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure
    Serena Spudich
    Department of Neurology, San Francisco General Hospital, University of California, San Francisco, CA 94110 3518, USA
    J Infect Dis 194:1686-96. 2006
  6. pmc Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 origin
    Richard W Price
    Department of Neurology, University of California, San Francisco, CA, USA
    Antivir Ther 13:369-74. 2008
  7. pmc Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection
    Elizabeth Sinclair
    Department of Medicine, University of California at San Francisco, San Francisco, CA, USA
    J Acquir Immune Defic Syndr 47:544-52. 2008
  8. pmc Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection
    Michael J Peluso
    Department of Neurology, Yale School of Medicine, New Haven, Connecticut, USA
    J Infect Dis 207:1703-12. 2013
  9. pmc Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden
    Serena Spudich
    Department of Neurology, University of California San Francisco, USA
    J Infect Dis 204:753-60. 2011
  10. pmc Antiretroviral therapy and central nervous system HIV type 1 infection
    Richard W Price
    Department of Neurology, University of California San Francisco, San Francisco General Hospital, 1001 Potrero Avenue, San Francisco, CA 94117, USA
    J Infect Dis 197:S294-306. 2008

Research Grants

  1. The Neuropathobiology of Primary HIV-1 Infection
    Serena S Spudich; Fiscal Year: 2010
  2. Central Nervous System Events in Primary HIV Infection
    Serena Spudich; Fiscal Year: 2007
  3. The Neuropathobiology of Primary HIV-1 Infection
    Serena Spudich; Fiscal Year: 2009
  4. The Neuropathobiology of Primary HIV-1 Infection
    Serena Spudich; Fiscal Year: 2009
  5. The Neuropathobiology of Primary HIV-1 Infection
    Serena S Spudich; Fiscal Year: 2010

Collaborators

Detail Information

Publications12

  1. ncbi request reprint HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremia
    Serena S Spudich
    Department of Neurology, University of California San Francisco, San Francisco, California, USA
    J Infect Dis 191:890-8. 2005
    ..Using an in vitro functional entry assay, we examined utilization of 2 principal coreceptors in cerebrospinal fluid (CSF) and plasma in 46 subjects...
  2. pmc The cerebrospinal fluid proteome in HIV infection: change associated with disease severity
    Thomas E Angel
    Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA
    Clin Proteomics 9:3. 2012
    ..abstract:..
  3. pmc Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection
    Lars Hagberg
    Department of Infectious Diseases, Sahlgrenska University Hospital, University of Gothenburg SE 41685 Sweden
    AIDS Res Ther 7:15. 2010
    ....
  4. pmc Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment
    Serena S Spudich
    Department of Neurology, University of California, San Francisco, USA
    BMC Infect Dis 5:98. 2005
    ..Because of its proximity to and shared barriers with the brain, cerebrospinal fluid (CSF) provides a useful window into and model of human CNS HIV infection...
  5. ncbi request reprint Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure
    Serena Spudich
    Department of Neurology, San Francisco General Hospital, University of California, San Francisco, CA 94110 3518, USA
    J Infect Dis 194:1686-96. 2006
    ..To characterize the effect of partially suppressive combination antiretroviral therapy on cerebrospinal fluid (CSF) human immunodeficiency virus (HIV)-1 RNA levels and CSF inflammation...
  6. pmc Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 origin
    Richard W Price
    Department of Neurology, University of California, San Francisco, CA, USA
    Antivir Ther 13:369-74. 2008
    ..Here, we define cerebrospinal fluid (CSF) enfuvirtide pharmacokinetics and present a case illustrating the use of enfuvirtide as a probe to trace the origins of CSF HIV-1 quasispecies...
  7. pmc Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection
    Elizabeth Sinclair
    Department of Medicine, University of California at San Francisco, San Francisco, CA, USA
    J Acquir Immune Defic Syndr 47:544-52. 2008
    ..To define the effect of antiretroviral therapy (ART) on activation of T cells in cerebrospinal fluid (CSF) and blood, and interactions of this activation with CSF HIV-1 RNA concentrations...
  8. pmc Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection
    Michael J Peluso
    Department of Neurology, Yale School of Medicine, New Haven, Connecticut, USA
    J Infect Dis 207:1703-12. 2013
    ..Cerebrospinal fluid (CSF) and neuroimaging abnormalities demonstrate neuronal injury during chronic AIDS, but data on these biomarkers during primary human immunodeficiency virus (HIV) infection is limited...
  9. pmc Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden
    Serena Spudich
    Department of Neurology, University of California San Francisco, USA
    J Infect Dis 204:753-60. 2011
    ..Although HIV enters the nervous system soon after transmission, the magnitude of infection and immunoactivation within the CNS during primary HIV infection (PHI) has not been characterized...
  10. pmc Antiretroviral therapy and central nervous system HIV type 1 infection
    Richard W Price
    Department of Neurology, University of California San Francisco, San Francisco General Hospital, 1001 Potrero Avenue, San Francisco, CA 94117, USA
    J Infect Dis 197:S294-306. 2008
    ..With better control of these severe disorders, attention has turned to the possible consequences of chronic silent infection and the issue of whether indolent, low-grade brain injury might require earlier treatment intervention...
  11. ncbi request reprint Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia
    Peter W Hunt
    Positive Health Program, San Francisco General Hospital, San Francisco, CA 94110, USA
    J Infect Dis 194:926-30. 2006
    ..CCR5 inhibitors may thus be best strategically used before salvage therapy and before significant CD4 + T cell depletion...
  12. pmc HIV-1-related central nervous system disease: current issues in pathogenesis, diagnosis, and treatment
    Serena Spudich
    Department of Neurology, Yale University School of Medicine, New Haven, Connecticut, USA
    Cold Spring Harb Perspect Med 2:a007120. 2012
    ....

Research Grants7

  1. The Neuropathobiology of Primary HIV-1 Infection
    Serena S Spudich; Fiscal Year: 2010
    ..In addition, revealing the early effects of antiretroviral treatment in the CNS may provide a new rationale for initiating antiretroviral therapy in early HIV-1 infection. ..
  2. Central Nervous System Events in Primary HIV Infection
    Serena Spudich; Fiscal Year: 2007
    ..Finally, the guidance of Drs. Price, Meyerhoff, and Hecht and support from UCSF's Neurology Department will allow the applicant to excel as an integral member of the academic community. ..
  3. The Neuropathobiology of Primary HIV-1 Infection
    Serena Spudich; Fiscal Year: 2009
    ..In addition, revealing the early effects of antiretroviral treatment in the CNS may provide a new rationale for initiating antiretroviral therapy in early HIV-1 infection. ..
  4. The Neuropathobiology of Primary HIV-1 Infection
    Serena Spudich; Fiscal Year: 2009
    ..In addition, revealing the early effects of antiretroviral treatment in the CNS may provide a new rationale for initiating antiretroviral therapy in early HIV-1 infection. ..
  5. The Neuropathobiology of Primary HIV-1 Infection
    Serena S Spudich; Fiscal Year: 2010
    ..In addition, revealing the early effects of antiretroviral treatment in the CNS may provide a new rationale for initiating antiretroviral therapy in early HIV-1 infection. ..